Glucophage Tablet Uses, Dosage and Side Effects in Pakistan

What Is Glucophage?

Glucophage is the brand name for metformin hydrochloride, a biguanide-class antidiabetic drug and Pakistan's most widely prescribed medicine for Type 2 diabetes mellitus. Originally developed in France in the 1950s and approved globally over subsequent decades, metformin has earned its place as the undisputed first-line pharmacological treatment for Type 2 diabetes according to both the World Health Organization (WHO) Essential Medicines List and the American Diabetes Association (ADA) Standards of Care.

In Pakistan, Glucophage is manufactured and distributed by Merck (Pakistan), a subsidiary of the German pharmaceutical giant. It is available in three standard strengths — 500 mg, 850 mg, and 1000 mg tablets — as well as an extended-release variant known as Glucophage XR, which releases metformin slowly over 24 hours to minimise gastrointestinal side effects. You will find Glucophage stocked at virtually every pharmacy chain across Pakistan, including Fazal Din & Sons, D.Watson, Shaheen Chemist, and thousands of local medical stores in Karachi, Lahore, Islamabad, Peshawar, and beyond. It is one of the most affordable chronic-disease medicines available in the country, a critical advantage for the millions of Pakistanis managing long-term diabetes.

Quick Facts

Glucophage at a Glance

Generic Name	Metformin Hydrochloride
Brand Name	Glucophage (Merck)
Drug Class	Biguanide antidiabetic
Available Strengths	500 mg, 850 mg, 1000 mg tablets; XR (extended-release) variants
Available in Pakistan	Yes — widely stocked at all major pharmacy chains
Prescription Required	Yes
Approximate Price in PK	Rs. 25–60 (generic, 10 tablets); Rs. 80–150 (Glucophage brand)
Common Uses	Type 2 diabetes, PCOS, pre-diabetes, metabolic syndrome

How Does Glucophage Work?

The mechanism of action of metformin is multi-faceted and, for many years, was not fully understood. Today, the scientific consensus points to three primary actions working together to lower blood glucose levels.

The most important effect is inhibition of hepatic gluconeogenesis. Metformin targets Complex I of the mitochondrial respiratory chain in liver cells (hepatocytes). By doing so, it reduces the production of ATP in the liver and activates AMP-activated protein kinase (AMPK), a cellular energy sensor often described as a master metabolic switch. Activation of AMPK suppresses the genes responsible for gluconeogenesis — the process by which the liver manufactures new glucose from non-carbohydrate precursors such as lactate, amino acids, and glycerol. In a person with Type 2 diabetes, the liver is inappropriately overproducing glucose even in the fed state, a major driver of elevated fasting blood sugar. Metformin corrects this.

The second mechanism is improved peripheral insulin sensitivity, particularly in skeletal muscle cells. Metformin facilitates glucose uptake into muscle by enhancing the translocation of GLUT4 transporters to the cell membrane, allowing glucose to enter cells more efficiently even when insulin signalling is impaired.

Critically, metformin does not stimulate insulin secretion from the pancreatic beta cells. This is why, when used as monotherapy, it has a very low risk of causing hypoglycaemia (dangerously low blood sugar) — a significant advantage over older diabetes medications such as glibenclamide and glipizide. Additionally, unlike many other antidiabetic agents, metformin is weight-neutral to mildly weight-reducing, making it especially suitable for the many overweight and obese Pakistani patients with Type 2 diabetes.

Glucophage Uses in Pakistan

Type 2 Diabetes Mellitus — First-Line Treatment

Glucophage is the cornerstone of Type 2 diabetes pharmacotherapy in Pakistan. According to WHO and ADA guidelines, it should be initiated at the time of diagnosis (alongside lifestyle modification) in almost all patients with Type 2 diabetes who can tolerate it. It can be used as monotherapy or combined with other antidiabetic agents as the disease progresses. Common combination partners in Pakistani clinical practice include:

• Sulfonylureas (glipizide, gliclazide, glibenclamide) — added when metformin monotherapy is insufficient
• DPP-4 inhibitors (sitagliptin, vildagliptin) — increasingly popular for their low hypoglycaemia risk
• SGLT-2 inhibitors (empagliflozin, dapagliflozin) — beneficial for patients with cardiovascular or kidney disease
• Insulin — added in advanced disease; metformin is typically continued alongside insulin to reduce insulin dose requirements

The target HbA1c for most adults with Type 2 diabetes in Pakistan is less than 7.0%, though individualised targets are set based on age, comorbidities, and risk of hypoglycaemia.

PCOS — Polycystic Ovary Syndrome

PCOS is one of the most common endocrine disorders affecting Pakistani women of reproductive age, with estimates suggesting it affects 8–20% of this population. Glucophage is widely prescribed by gynaecologists and endocrinologists across Pakistan for PCOS — an off-label but robustly evidence-based use. In PCOS, insulin resistance is a central pathophysiological driver: elevated insulin stimulates the ovaries to produce excess androgens (male hormones), disrupting ovulation and causing the characteristic symptoms of irregular periods, acne, weight gain, and excess body hair (hirsutism).

Metformin addresses this by reducing insulin resistance, which in turn lowers circulating insulin levels and reduces ovarian androgen production. Clinical benefits observed in Pakistani patients include:

• Restoration of regular menstrual cycles in many patients
• Reduction in testosterone and LH:FSH ratio within 2–3 months
• Improved ovulation rates, supporting fertility
• Modest weight reduction
• Reduced risk of progression to Type 2 diabetes

Full menstrual and hormonal benefits typically require 3–6 months of consistent daily use. Patients should not discontinue early if they do not see results in the first month.

Pre-Diabetes — Prevention of Type 2 Diabetes

Pakistan has one of the highest rates of pre-diabetes in the world. Pre-diabetes is defined as fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%. The landmark Diabetes Prevention Program (DPP) trial demonstrated that metformin reduced progression from pre-diabetes to Type 2 diabetes by 31% over 3 years. While lifestyle modification remains the first recommendation, Glucophage is appropriate for high-risk individuals: those under 60 years old, obese, with a family history of diabetes, or with gestational diabetes history. Many Pakistani endocrinologists now initiate metformin in such patients proactively.

Metabolic Syndrome

Metabolic syndrome — a cluster of abdominal obesity, elevated triglycerides, low HDL cholesterol, hypertension, and impaired fasting glucose — is increasingly prevalent in urban Pakistan due to sedentary lifestyles and high-carbohydrate diets. Metformin helps address the insulin resistance component of metabolic syndrome, and is commonly included in the management plan alongside statins, antihypertensives, and lifestyle counselling.

Glucophage Dosage Guide

Dosing must always be individualised by your doctor. The general approach prioritises a low-and-slow titration to minimise gastrointestinal side effects, with food always accompanying the tablet.

Standard Glucophage Dosing Schedule

Week 1–2	500 mg once daily with dinner
Week 3–4	500 mg twice daily (breakfast + dinner)
Week 5–6	500 mg three times daily or 850 mg twice daily
Maintenance	1000–2000 mg/day in divided doses
Maximum dose	2000 mg/day (some guidelines allow 2550 mg)
Glucophage XR	500–2000 mg once daily at night with dinner
Paediatric (10+ years)	500–1000 mg/day; titrate slowly

Important dosing rules:

• Always take with food — this is not optional. Taking on an empty stomach dramatically increases nausea and diarrhoea.
• Do NOT crush, split, or chew Glucophage XR tablets. The extended-release mechanism is destroyed if the tablet is broken.
• If you miss a dose, take it with your next meal. Never double up on doses.
• Dose reduction is required if kidney function declines (eGFR below 45 mL/min/1.73m²).
• Hold Glucophage 48 hours before any contrast dye procedure (CT scan with contrast, cardiac angiography, angioplasty) and restart only after kidney function is confirmed normal 48 hours after the procedure.

Side Effects of Glucophage

Common Side Effects — Gastrointestinal

Gastrointestinal side effects are the most frequently reported issue with Glucophage, affecting approximately 20–30% of patients, particularly in the early weeks of treatment. These include:

• Nausea
• Diarrhoea or loose stools
• Stomach cramps or abdominal discomfort
• Metallic or bitter taste in the mouth
• Loss of appetite (which can be beneficial for weight management)

The good news: these side effects almost always resolve on their own within 2–4 weeks as the body adjusts. Taking the tablet with the largest meal of the day and starting at the lowest dose (500 mg) with slow titration are the most effective strategies. Switching from standard tablets to Glucophage XR (extended-release) significantly reduces GI side effects for patients who cannot tolerate the standard form.

Serious but Rare — Lactic Acidosis

Lactic acidosis is the most feared complication of metformin therapy. It occurs when metformin accumulates in the body to toxic levels, leading to a dangerous build-up of lactic acid in the blood. However, it is extremely rare in patients with normal kidney function — the estimated incidence is less than 0.01 cases per 1,000 patient-years. Risk factors that predispose patients to lactic acidosis include:

• Significant kidney impairment (eGFR below 30 mL/min/1.73m²)
• Liver failure or severe liver disease
• Heavy alcohol consumption
• Decompensated heart failure
• Acute serious illness (sepsis, dehydration, major surgery)

Symptoms include weakness, muscle pain, difficulty breathing, stomach pain, nausea, vomiting, dizziness, and irregular heartbeat. If any of these occur, stop the medication and seek emergency care immediately.

Long-Term — Vitamin B12 Deficiency

Metformin interferes with calcium-dependent absorption of Vitamin B12 in the terminal ileum. After 3 or more years of continuous use, a measurable decline in serum B12 levels occurs in approximately 10–30% of patients. Severe deficiency can cause peripheral neuropathy, anaemia, and cognitive decline — symptoms that can be mistaken for diabetic neuropathy. All patients on long-term Glucophage should have annual Vitamin B12 levels checked and supplement if levels fall below normal.

Weight Effect

Unlike sulfonylureas and insulin, metformin is weight-neutral to mildly weight-reducing in most patients. This is a significant clinical advantage for the large proportion of Pakistani Type 2 diabetes patients who are overweight or obese, as weight gain worsens insulin resistance and cardiovascular risk.

Who Should NOT Take Glucophage

Glucophage is contraindicated in certain situations where accumulation or toxicity risk is unacceptably high:

• Severe kidney disease — eGFR below 30 mL/min/1.73m² (Stage 4–5 CKD). Use with caution and dose reduction between eGFR 30–45.
• Before contrast dye procedures — Must be held for 48 hours before any imaging procedure using iodinated contrast dye (CT angiography, coronary angiography, IVP). Restart only after confirming normal kidney function 48 hours post-procedure.
• Active liver failure or alcoholic liver disease — Impaired lactate clearance increases lactic acidosis risk.
• Significant alcohol use — Alcohol potentiates lactic acid accumulation.
• Decompensated heart failure — Tissue hypoxia increases lactic acidosis risk.
• Type 1 diabetes — Glucophage has no meaningful effect on blood sugar in Type 1 diabetes, where the pancreas produces no insulin.
• Pregnancy — Discuss carefully with your doctor. Some guidelines permit metformin in gestational diabetes and for PCOS patients trying to conceive, but evidence is still evolving. Never self-medicate during pregnancy.

Glucophage vs Generic Metformin in Pakistan

Glucophage and generic metformin tablets contain the same active ingredient — metformin hydrochloride — and generic versions are bioequivalent when manufactured under proper quality standards. Several generic brands are available in Pakistan:

• Metformin tablets (various local manufacturers)
• Diabex (manufactured by CCL Pharmaceuticals)
• Formin (various)
• Metforal

Generic metformin is often significantly cheaper — a strip of 10 tablets may cost Rs. 25–60 compared to Rs. 80–150 for branded Glucophage. For most stable patients on a well-tolerated regimen, cost-effective generic substitution under medical supervision is reasonable. The XR (extended-release) formulation in particular — Glucophage XR — is often preferred by Pakistani doctors for patients who experience persistent GI intolerance with standard tablets, and branded XR versions may be better standardised in their release profiles. Any switch between standard and XR formulations, or between brands, should be discussed with your doctor.

Monitoring While on Glucophage

Effective diabetes management is not just about taking the tablet — it requires regular monitoring to confirm the medication is working safely and to catch problems early. Your doctor should arrange the following tests:

• HbA1c (glycated haemoglobin) — Every 3 months initially until stable, then every 6 months. Target for most adults: less than 7.0%. This single test reflects your average blood glucose over the past 2–3 months.
• Kidney function (serum creatinine and eGFR) — Baseline before starting, then annually if normal. More frequent if you have existing kidney disease, hypertension, or are taking NSAIDs. Glucophage dose must be adjusted or stopped if eGFR declines.
• Vitamin B12 — Baseline, then annually after 3 years of use. Supplement if deficient.
• Blood glucose self-monitoring — Fasting glucose (first thing in the morning, before eating) and post-prandial glucose (2 hours after a meal). Targets: fasting 80–130 mg/dL; post-meal below 180 mg/dL.
• Liver function tests (LFTs) — At baseline if liver disease is suspected. Routine monitoring is not required in patients without liver risk factors.
• Lipid panel — Annually, as dyslipidaemia is common in Type 2 diabetes and drives cardiovascular risk.

Glucophage in Pakistan — Availability and Cost

Glucophage is freely available at all major pharmacy chains across Pakistan's major cities and is stocked at district-level hospital pharmacies and government health centres in most provinces. It appears on the National Essential Medicines List of Pakistan, which means government hospitals are mandated to dispense it. However, availability at public sector facilities can be inconsistent in rural areas.

Price breakdown (approximate, June 2026):

• Generic metformin 500 mg, strip of 10 tablets: Rs. 25–60
• Glucophage 500 mg (Merck), strip of 10 tablets: Rs. 80–120
• Glucophage 1000 mg, strip of 10 tablets: Rs. 130–180
• Glucophage XR 500 mg, strip of 10 tablets: Rs. 110–160

Prices vary between pharmacy chains and cities. Always keep a 2-week supply buffer, as chronic medication shortages can occur. A prescription from a PMDC-registered doctor is legally required to purchase Glucophage — do not obtain it from pharmacies that dispense without prescription, as unsupervised use carries real risks.

Frequently Asked Questions